Taking everything into account, NDRA scores 2 out of 10 in our fundamental rating. NDRA was compared to 187 industry peers in the Health Care Equipment & Supplies industry. NDRA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NDRA is valued expensive and it does not seem to be growing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -407.68% | ||
| ROE | -4671.65% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -88.52 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.31 | ||
| Quick Ratio | 1.31 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:NDRA (12/18/2025, 8:00:01 PM)
5.06
+0.12 (+2.43%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 34.54 | ||
| P/tB | 34.54 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -407.68% | ||
| ROE | -4671.65% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | -21.79% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.31 | ||
| Quick Ratio | 1.31 | ||
| Altman-Z | -88.52 |
ChartMill assigns a fundamental rating of 2 / 10 to NDRA.
ChartMill assigns a valuation rating of 1 / 10 to ENDRA LIFE SCIENCES INC (NDRA). This can be considered as Overvalued.
ENDRA LIFE SCIENCES INC (NDRA) has a profitability rating of 0 / 10.
The Earnings per Share (EPS) of ENDRA LIFE SCIENCES INC (NDRA) is expected to grow by 98.75% in the next year.